Industry News AriBio / Fosun Pharma BioSpace

AriBio's PDE5 inhibitor AR1001 wins Phase 3 only in the monotherapy subgroup

  • POLARIS-AD randomized 1,535 early Alzheimer's patients to oral AR1001 or placebo for 52 weeks, with two primary analyses, either of which could count as success.
  • The monotherapy subgroup (604 patients, no cholinesterase inhibitor or memantine) slowed decline by 31% and met its endpoint; the full population showed only 7%, not significant.
  • Diarrhea and treatment discontinuations were higher on drug. AriBio will talk to the FDA; Fosun, holding a $60M option, is deciding whether to exercise it.
Points Based on public reports

A win in a prespecified subgroup of a missed full-population analysis is a thin basis for filing; the multiplicity design lets it count, but regulators will ask why symptomatic therapy would mask a disease-modifying effect. The comparison with anti-amyloid antibodies is cross-trial and should not be trusted. Fosun's decision on the option is the sharper commercial read than the press release.